Status:
NOT_YET_RECRUITING
Cognitive Remediation
Lead Sponsor:
Cutter Lindbergh
Collaborating Sponsors:
National Institute on Aging (NIA)
Conditions:
Aging
Inflammation
Eligibility:
All Genders
60+ years
Phase:
NA
Brief Summary
The goal of this clinical trial is to determine if a neuroscience-based computerized cognitive remediation ("brain training") program can treat neurocognitive dysfunction (i.e., memory or thinking dif...
Detailed Description
A significant minority of older adults display persistent cognitive impairments after the acute phase of a viral infection, referred to as Postviral Neurocognitive Dysfunction (PND). Underlying mechan...
Eligibility Criteria
Inclusion
- age ≥ 60 years old
- prior history of COVID-19 that was confirmed with viral testing (e.g., positive laboratory test or positive at-home rapid test)
- cognitive symptoms (e.g., memory or thinking concerns) following COVID- 19 infection that have lasted for at least 12 weeks and are still present
- clinically meaningfully subjective cognitive concerns (i.e., T-score \< 40) on the PROMIS-Cognitive Function Scale
- objective evidence of cognitive decline, as defined by performance on standardized measures of executive functioning, memory, or processing speed from the NIH Toolbox Cognition Battery that is at least 1 standard deviation below estimated premorbid cognitive functioning
- fluent in English language
- off psychiatric medication or on a stable dose for at least 8 weeks
Exclusion
- history of neurological disorder with potential to interfere with study participation or confound results (e.g., uncontrolled seizure disorder, moderate to severe traumatic brain injury or stroke with persistent neurological deficits)
- history of dementia and/or dementia range performance on the Mini- Mental State Examination (i.e., score of less than or equal to 23)
- prior diagnosis of Mild Cognitive Impairment (MCI) or Mild Neurocognitive Disorder unrelated to the participant's history of COVID-19
- history of severe psychiatric illness that may interfere with study participation or confound results (e.g., bipolar disorder, schizophrenia, or other psychotic disorder)
- history of significant neurodevelopmental condition that may interfere with study participation or confound results (e.g., intellectual disability, autism spectrum disorder, or specific learning disorder with impairment in reading)
- alcohol or other substance use disorder within the past 2 years
- significant sensory impairments (e.g., blindness) that would interfere with the ability to complete neuropsychological measures or engage in the tablet-based intervention
- performance that is below expectation on a test of effort and validity
Key Trial Info
Start Date :
January 15 2026
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
April 30 2030
Estimated Enrollment :
75 Patients enrolled
Trial Details
Trial ID
NCT07171450
Start Date
January 15 2026
End Date
April 30 2030
Last Update
November 21 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
UConn Health
Farmington, Connecticut, United States, 06030